Stay updated on Umbralisib Plus Pembrolizumab in Hodgkin Lymphoma Clinical Trial

Sign up to get notified when there's something new on the Umbralisib Plus Pembrolizumab in Hodgkin Lymphoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Umbralisib Plus Pembrolizumab in Hodgkin Lymphoma Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    Page revision updated from v3.4.2 to v3.4.3.
    Difference
    0.1%
    Check dated 2026-03-11T11:44:15.000Z thumbnail image
  2. Check
    13 days ago
    No Change Detected
  3. Check
    20 days ago
    No Change Detected
  4. Check
    34 days ago
    Change Detected
    Summary
    Revision: v3.4.2 was added and the prior funding notice (v3.4.1) was removed; there are no changes to study content, eligibility criteria, or outcomes. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2026-02-11T01:44:51.000Z thumbnail image
  5. Check
    41 days ago
    Change Detected
    Summary
    A government funding/status notice was added to the page footer and the site revision updated to v3.4.1 (replacing v3.4.0). To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2026-02-03T22:45:59.000Z thumbnail image
  6. Check
    48 days ago
    Change Detected
    Summary
    Added a glossary toggle. Made minor wording/casing updates to update log and footer metadata, and updated the page revision.
    Difference
    0.2%
    Check dated 2026-01-27T21:16:30.000Z thumbnail image
  7. Check
    84 days ago
    Change Detected
    Summary
    Added a Locations section with the Washington site listed. The footer revision note was updated to v3.3.3 and the HHS Vulnerability Disclosure and Washington Locations entries were removed.
    Difference
    0.2%
    Check dated 2025-12-22T22:28:45.000Z thumbnail image
  8. Check
    106 days ago
    Change Detected
    Summary
    Revision updated from v3.3.1 to v3.3.2 on the page; no study content or user-facing details appear to have changed.
    Difference
    0.1%
    Check dated 2025-12-01T16:21:02.000Z thumbnail image

Stay in the know with updates to Umbralisib Plus Pembrolizumab in Hodgkin Lymphoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Umbralisib Plus Pembrolizumab in Hodgkin Lymphoma Clinical Trial page.